Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR. (Q53130491)

From Wikidata

Jump to navigation Jump to search

scientific article published on 4 April 2016

Language	Label	Description	Also known as
English	Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR.	scientific article published on 4 April 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27041702

Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27041702

author name string

Atsuko Ashida

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27041702

Kaori Sakaizawa

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27041702

Asuka Mikoshiba

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27041702

Hisashi Uhara

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27041702

Ryuhei Okuyama

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27041702

publication date

4 April 2016

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27041702

International Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27041702

21

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27041702

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27041702

981-988

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27041702

Systemic treatment for BRAF-mutant melanoma: where do we go next?

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Cell-free nucleic acids as biomarkers in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Analysis of circulating tumor DNA to monitor metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Digital PCR as a novel technology and its potential implications for molecular diagnostics

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Minimal residual disease in breast cancer: in blood veritas

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Assessment of BRAF and KIT mutations in Japanese melanoma patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Circulating mutant DNA to assess tumor dynamics

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-0976-Y

21 January 2018

Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid, biochemical markers of melanoma progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/27041702

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of multiple serum markers in advanced melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27041702

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/27041702

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significance of allelic percentage of BRAF c.1799T > A (V600E) mutation in papillary thyroid carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27041702

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10147-016-0976-Y

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27041702

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27041702

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53130491&oldid=2212004403"